Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM471KJ)

• Drug Name: Omeprazole Drug Info
• Synonyms: Losec (TN)

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Approved	[1]
Gastric ulcer	DA60	Approved	[1]
Gastrinoma	2C10.1	Approved	[1]
Gastroesophageal reflux disease	DA22.Z	Approved	[2]
Laryngeal disorder		Approved	[1]
Nausea	MD90	Approved	[1]
Peptic esophagitis		Approved	[1]
Peptic ulcer	DA61	Approved	[1]
Congenital laryngomalacia		Investigative	[1]

• Therapeutic Class: Antiulcer Agents
• Cross-matching ID:
  PubChem CID: 4594
  ChEBI ID: CHEBI:77260
  CAS Number: CAS 73590-58-6
  TTD Drug ID: DM471KJ
  VARIDT Drug ID: DR00387
  INTEDE Drug ID: DR1196
  ACDINA Drug ID: D00489

Molecule-Related Drug Atlas

Drug(s) Targeting Gastric H(+)/K(+) ATPase (Proton pump)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pantoprazole	DMSVOCZ	Gastrinoma	2C10.1	Approved	[3]
Dexlansoprazole	DM1DBV5	Erosive esophagitis	DA25.0	Approved	[3]
Esomeprazole	DM7BN0X	Cystic fibrosis	CA25	Approved	[3]
Vonoprazan	DMO6315	Helicobacter infection	DA42-DA63	Approved	[15]
RQ-00000004	DM9T8OF	Gastroesophageal reflux disease	DA22.Z	Phase 3	[16]
YH-4808	DMCHFB0	Duodenal ulcer	DA63	Phase 2	[17]
S-tenatoprazole	DMJ1DIB	Peptic ulcer	DA61	Phase 2	[18]
AZD-0865	DMM0N1F	Gastrointestinal disease	DE2Z	Phase 2	[19]
LEMINOPRAZOLE	DMBKNJT	Ulcerative colitis	DD71	Discontinued in Preregistration	[20]
SKF-96067	DMXW1Y3	Peptic ulcer	DA61	Discontinued in Phase 3	[21]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[22]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[23]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[24]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[25]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[24]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[26]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[24]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[27]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[28]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[29]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[30]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[31]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[33]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[34]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[35]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[36]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[30]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[5]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[73]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[74]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[75]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[76]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[77]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[77]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[78]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[79]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[80]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[81]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[37]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[38]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[39]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[40]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[41]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[42]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[43]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[44]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[45]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[40]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[73]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[74]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[79]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[79]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[82]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[86]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[87]

Drug(s) Metabolized By Cytochrome P450 2C18 (CYP2C18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[46]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[47]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[48]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[50]
Methadone	DMTW6IU	Advanced cancer	2A00-2F9Z	Approved	[51]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[52]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[46]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[53]

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[54]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[55]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[55]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[46]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[56]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[57]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[58]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[55]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[59]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[48]

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[60]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[61]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[62]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[46]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[63]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[46]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[64]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[65]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[68]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[60]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[69]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[70]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[46]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[71]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[47]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[72]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[48]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[88]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[89]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[90]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[91]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[92]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[93]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[94]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[95]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[96]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[97]

Drug(s) Affected By Alcohol dehydrogenase 1C (ADH1C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[98]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[99]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[100]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[9]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[102]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[100]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[103]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[104]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[104]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[104]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[105]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[106]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[107]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[108]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[109]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[110]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[111]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[112]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[113]
Methysergide	DM1EF73	Migraine	8A80	Approved	[114]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[115]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[116]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[114]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[117]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[99]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[118]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[119]

Drug(s) Affected By Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[120]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[121]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[123]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[124]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[125]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[126]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[127]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[128]

Drug(s) Affected By Retinaldehyde dehydrogenase 3 (ALDH1A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[111]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[119]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[129]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[130]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[131]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[132]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[132]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[133]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[133]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[134]

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[89]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[136]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[137]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[138]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[139]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[140]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[141]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[142]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[143]

Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[144]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[145]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[9]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[146]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[147]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[148]
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[149]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[150]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[151]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[152]

Drug(s) Affected By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[153]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[154]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[155]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[156]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[157]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[158]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[159]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[160]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[99]

Drug(s) Affected By Solute carrier organic anion transporter family member 1A2 (SLCO1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trospium chloride	DM32XZT	Discovery agent	N.A.	Approved	[161]
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[162]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[163]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[164]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[134]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[165]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[166]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[167]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[168]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[169]

Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[170]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[170]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[171]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[111]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[172]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[173]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[174]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[175]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[176]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[177]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[12]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[178]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[178]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[103]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[12]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[178]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[114]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[12]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[179]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[12]

Drug(s) Affected By Aryl hydrocarbon receptor nuclear translocator (ARNT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[180]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[116]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[181]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[182]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[183]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[184]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[185]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[186]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[183]

Drug(s) Affected By Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[187]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[188]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[189]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[190]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[191]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[192]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[193]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[194]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[195]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[196]

Drug(s) Affected By C-X-C chemokine receptor type 4 (CXCR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[197]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[198]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[199]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[200]
Carfilzomib	DM48K0X	Multiple myeloma	2A83	Approved	[201]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[193]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[199]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[202]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[203]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[204]

Drug(s) Affected By Transmembrane protease serine 2 (TMPRSS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[10]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[10]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[198]
Selenium	DM25CGV	N. A.	N. A.	Approved	[205]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[10]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[10]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[10]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[10]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[10]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[206]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[206]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[207]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[208]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[209]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[206]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[206]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[206]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[210]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[211]

Drug(s) Affected By Phospholipid-transporting ATPase ABCA1 (ABCA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[212]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[213]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[117]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[214]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[99]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[215]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[216]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[217]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[218]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[219]

Drug(s) Affected By Prolactin (PRL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[220]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[221]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[222]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[223]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[224]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[225]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[226]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[227]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[228]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[229]

Drug(s) Affected By HLA class I histocompatibility antigen, B alpha chain (HLA-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[230]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[231]
Allopurinol	DMLPAOB	Gout	FA25	Approved	[232]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[233]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[234]
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[235]
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[236]
Flucloxacillin	DMNUWST	Bacterial infection	1A00-1C4Z	Approved	[237]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[238]

Drug(s) Affected By Cathepsin B (CTSB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[239]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[197]
Selenium	DM25CGV	N. A.	N. A.	Approved	[205]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[117]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[119]
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[240]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[241]
Propylthiouracil	DM6D7N8	Hyperthyroidism	5A02	Approved	[242]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[243]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[244]

Drug(s) Affected By Heme oxygenase 1 (HMOX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[245]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[246]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[143]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[247]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[248]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[249]
Selenium	DM25CGV	N. A.	N. A.	Approved	[250]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[251]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[252]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[253]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[254]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[255]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[256]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[257]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[258]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[259]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[258]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[260]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[261]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[262]

Drug(s) Affected By HLA class I histocompatibility antigen, alpha chain G (HLA-G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[205]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[235]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[224]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[263]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[235]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[264]
Lisinopril	DMUOK4C	Chronic heart failure	BD1Z	Approved	[235]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[235]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[235]
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[235]

Drug(s) Affected By DNA damage-inducible transcript 3 protein (DDIT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[246]
Triacetin	DM0AEPG	Onychomycosis	EE12.1	Approved	[265]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[266]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[267]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[268]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[269]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[270]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[271]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[117]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[272]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[273]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[274]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[275]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[276]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[277]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[278]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[259]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[279]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[280]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[281]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[282]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[283]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[284]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[285]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[286]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[287]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[288]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[289]

Drug(s) Affected By Cytosolic phospholipase A2 (PLA2G4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[290]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[119]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[129]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[291]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[292]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[293]
Budesonide	DMJIBAW	Allergic rhinitis	CA08.0	Approved	[294]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[126]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[295]

Drug(s) Affected By Hepcidin (HAMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[296]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[297]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[117]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[124]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[298]
Cantharidin	DMBP5N3	Molluscum contagiosum infection	1E76	Approved	[299]
Papaverine	DMCA9QP	Brain ischaemia	8B1Z	Approved	[299]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[300]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[299]

Drug(s) Affected By Caspase-8 (CASP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[301]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[302]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[303]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[304]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[305]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[306]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[257]
Selenium	DM25CGV	N. A.	N. A.	Approved	[205]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[307]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[224]

Drug(s) Affected By Angiotensin-converting enzyme 2 (ACE2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Captopril	DM458UM	Chronic heart failure	BD1Z	Approved	[308]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[10]
Dantrolene	DM1D8XY	Hyperthermia	MG26	Approved	[10]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[10]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[10]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[10]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[10]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[10]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[10]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[10]

Drug(s) Affected By Potassium-transporting ATPase alpha chain 2 (ATP12A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[309]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[295]
Capecitabine	DMTS85L	Adenocarcinoma	2D40	Approved	[310]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[311]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[312]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[313]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastric H(+)/K(+) ATPase (Proton pump)	TTLOKXP	ATP4A_HUMAN; ATP4B_HUMAN	Modulator	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[6]
Mephenytoin 4-hydroxylase (CYP2C19) Main DME	DEGTFWK	CP2CJ_HUMAN	Substrate	[5]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[7]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[8]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alcohol dehydrogenase 1C (ADH1C)	OTO1DV7F	ADH1G_HUMAN	Gene/Protein Processing	[9]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)	OTAYZZE6	AL3A1_HUMAN	Gene/Protein Processing	[9]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[10]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Gene/Protein Processing	[11]
Aryl hydrocarbon receptor nuclear translocator (ARNT)	OTMSIEZY	ARNT_HUMAN	Protein Interaction/Cellular Processes	[11]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[12]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Gene/Protein Processing	[13]
C-X-C chemokine receptor type 4 (CXCR4)	OTUFSBX2	CXCR4_HUMAN	Gene/Protein Processing	[11]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[14]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Protein Interaction/Cellular Processes	[14]

References

• [1] Omeprazole FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4279).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
• [5] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [6] Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.
• [7] Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009 Apr;37(4):821-6.
• [8] Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 Oct;24(10):1081-7.
• [9] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [10] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [11] Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
• [12] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [13] A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. Biochem Pharmacol. 2010 Dec 1;80(11):1754-61.
• [14] Omeprazole induces apoptosis in normal human polymorphonuclear leucocytes. Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):73-85. doi: 10.1177/039463200802100109.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008
• [16] N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9.
• [17] Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil.2012 Aug;24(8):697-704.
• [18] Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in heal... Aliment Pharmacol Ther. 2004 Mar 15;19(6):655-62.
• [19] Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205.
• [20] Vasoinhibitory effect of leminoprazole, a H+,K(+)-ATPase inhibitor, on rat aortic rings. Gen Pharmacol. 1996 Jan;27(1):117-21.
• [21] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [22] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [23] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [24] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [25] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [26] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [27] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [28] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [29] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [30] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [31] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [32] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [33] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [34] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [35] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [36] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [37] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [38] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [39] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [40] Drug Interactions Flockhart Table
• [41] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [42] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [43] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [44] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [45] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [46] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [47] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [48] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [49] Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
• [50] Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
• [51] Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
• [52] CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
• [53] Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
• [54] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [55] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [56] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [57] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [58] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [59] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [60] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [61] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [62] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [63] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [64] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [65] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [66] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [67] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [68] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [69] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [70] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [71] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [72] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [73] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [74] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [75] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [76] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [77] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [78] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [79] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [80] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [81] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [82] Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
• [83] Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
• [84] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [85] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [86] Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
• [87] Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 2000 Mar;22(3):360-6.
• [88] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [89] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [90] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [91] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [92] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [93] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [94] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [95] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [96] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [97] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [98] An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
• [99] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [100] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [101] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [102] Proteomics analysis of the proliferative effect of low-dose ouabain on human endothelial cells. Biol Pharm Bull. 2007 Feb;30(2):247-53. doi: 10.1248/bpb.30.247.
• [103] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [104] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [105] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [106] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [107] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [108] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [109] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [110] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [111] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [112] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [113] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [114] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [115] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [116] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [117] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [118] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [119] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [120] TGF-1 signaling protects retinal ganglion cells from oxidative stress via modulation of the HO-1/Nrf2 pathway. Chem Biol Interact. 2020 Nov 1;331:109249. doi: 10.1016/j.cbi.2020.109249. Epub 2020 Sep 24.
• [121] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [122] RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol. 2007 Jan;59(1):127-36. doi: 10.1007/s00280-006-0233-6. Epub 2006 Apr 14.
• [123] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [124] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [125] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [126] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [127] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [128] Nucleophosmin in the pathogenesis of arsenic-related bladder carcinogenesis revealed by quantitative proteomics. Toxicol Appl Pharmacol. 2010 Jan 15;242(2):126-35. doi: 10.1016/j.taap.2009.09.016. Epub 2009 Oct 7.
• [129] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [130] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [131] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [132] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [133] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [134] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [135] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [136] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [137] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [138] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [139] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [140] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [141] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [142] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [143] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [144] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [145] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [146] Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
• [147] Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
• [148] Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
• [149] Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
• [150] Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
• [151] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [152] Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.
• [153] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [154] Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
• [155] Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
• [156] Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007 Dec;20(6):875-81.
• [157] Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
• [158] Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
• [159] Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug;314(2):626-35. doi: 10.1124/jpet.105.086504. Epub 2005 Apr 21.
• [160] Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
• [161] Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
• [162] Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
• [163] Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
• [164] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [165] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [166] The SLCO1A2 gene, encoding human organic anion-transporting polypeptide 1A2, is transactivated by the vitamin D receptor. Mol Pharmacol. 2012 Jul;82(1):37-46. doi: 10.1124/mol.112.077909. Epub 2012 Apr 3.
• [167] UDCA and CDCA alleviate 17-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats. Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25. doi: 10.1016/j.taap.2016.10.011. Epub 2016 Oct 12.
• [168] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [169] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [170] Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
• [171] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
• [172] ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
• [173] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [174] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [175] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [176] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [177] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
• [178] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [179] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [180] Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol. 2006 Nov;70(5):1664-71. doi: 10.1124/mol.106.025817. Epub 2006 Jul 31.
• [181] Single and concerted effects of benzo[a]pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon carcinoma cell line Caco-2. Toxicol In Vitro. 2011 Apr;25(3):671-83.
• [182] Ligand-independent activation of AhR by hydroquinone mediates benzene-induced hematopoietic toxicity. Chem Biol Interact. 2022 Mar 1;355:109845. doi: 10.1016/j.cbi.2022.109845. Epub 2022 Feb 4.
• [183] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [184] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [185] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [186] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [187] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [188] Oxidative stress modulates expression of immune checkpoint genes via activation of AhR signaling. Toxicol Appl Pharmacol. 2022 Dec 15;457:116314. doi: 10.1016/j.taap.2022.116314. Epub 2022 Nov 9.
• [189] Profiling of enantiopure drugs towards aryl hydrocarbon (AhR), glucocorticoid (GR) and pregnane X (PXR) receptors in human reporter cell lines. Chem Biol Interact. 2014 Feb 5;208:64-76. doi: 10.1016/j.cbi.2013.11.018. Epub 2013 Dec 6.
• [190] Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
• [191] Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
• [192] Quercetin, quercetin glycosides and taxifolin differ in their ability to induce AhR activation and CYP1A1 expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1746-52.
• [193] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [194] Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
• [195] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [196] The inhibitory mechanisms of the tyrosine kinase inhibitors herbimycin a, genistein, and tyrphostin B48 with regard to the function of the aryl hydrocarbon receptor in Caco-2 cells. Biosci Biotechnol Biochem. 2010;74(1):36-43. doi: 10.1271/bbb.90438. Epub 2010 Jan 7.
• [197] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [198] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [199] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [200] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [201] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
• [202] Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-B signaling in cervical cancer. Ann Surg Oncol. 2014 Dec;21 Suppl 4:S687-95. doi: 10.1245/s10434-014-3812-5. Epub 2014 Jul 22.
• [203] Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells. Leuk Res. 2006 Feb;30(2):123-35. doi: 10.1016/j.leukres.2005.06.009. Epub 2005 Jul 25.
• [204] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [205] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [206] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [207] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [208] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [209] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [210] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [211] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [212] Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008 Dec;58(12):3675-83.
• [213] Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
• [214] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [215] Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
• [216] Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
• [217] Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1533-41. doi: 10.1016/j.bbrc.2005.04.071.
• [218] Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
• [219] Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol. 2004 Feb 1;67(3):411-9. doi: 10.1016/j.bcp.2003.09.014.
• [220] Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
• [221] [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
• [222] Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
• [223] Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
• [224] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [225] The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
• [226] Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
• [227] The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
• [228] Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
• [229] Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
• [230] Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008 Oct;9(10):1543-6. doi: 10.2217/14622416.9.10.1543.
• [231] Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010 Mar;11(3):349-56. doi: 10.2217/pgs.09.162.
• [232] HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4134-9. doi: 10.1073/pnas.0409500102. Epub 2005 Mar 2.
• [233] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [234] HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013 Jul;54(7):1307-14. doi: 10.1111/epi.12217. Epub 2013 May 20.
• [235] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [236] Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002 Mar 30;359(9312):1121-2. doi: 10.1016/S0140-6736(02)08158-8.
• [237] HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009 Jul;41(7):816-9. doi: 10.1038/ng.379. Epub 2009 May 31.
• [238] HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013 Jul 9;8(7):e68111. doi: 10.1371/journal.pone.0068111. Print 2013.
• [239] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [240] Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism. Cancer Res. 2008 Jul 1;68(13):5291-300. doi: 10.1158/0008-5472.CAN-08-0222.
• [241] Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line. Neurochem Res. 2012 Feb;37(2):370-80. doi: 10.1007/s11064-011-0620-1. Epub 2011 Oct 4.
• [242] Thyroid organotypic rat and human cultures used to investigate drug effects on thyroid function, hormone synthesis and release pathways. Toxicol Appl Pharmacol. 2012 Apr 1;260(1):81-8. doi: 10.1016/j.taap.2012.01.029. Epub 2012 Feb 8.
• [243] Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization. Autophagy. 2016 Nov;12(11):2213-2229. doi: 10.1080/15548627.2016.1213927. Epub 2016 Sep 16.
• [244] Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
• [245] Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
• [246] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [247] Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis. 2010;28(6):792-8. doi: 10.1159/000324287. Epub 2011 Apr 27.
• [248] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [249] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [250] High selenium status in individuals exposed to arsenic through coal-burning in Shaanxi (PR of China) modulates antioxidant enzymes, heme oxygenase-1 and DNA damage. Clin Chim Acta. 2010 Sep 6;411(17-18):1312-8.
• [251] Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
• [252] Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep. 2008 Aug;20(2):379-84.
• [253] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [254] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [255] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [256] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [257] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [258] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [259] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [260] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [261] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [262] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [263] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [264] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [265] Induction of CCAAT/enhancer-binding protein-homologous protein by cigarette smoke through the superoxide anion-triggered PERK-eIF2 pathway. Toxicology. 2011 Sep 5;287(1-3):105-12. doi: 10.1016/j.tox.2011.06.005. Epub 2011 Jun 15.
• [266] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [267] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [268] Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
• [269] High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
• [270] Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci. 2014 Jan;137(1):234-48. doi: 10.1093/toxsci/kft232. Epub 2013 Oct 17.
• [271] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [272] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [273] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [274] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [275] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [276] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [277] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [278] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [279] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [280] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [281] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [282] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [283] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [284] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [285] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [286] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [287] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [288] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [289] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [290] Troglitazone but not conjugated linoleic acid reduces gene expression and activity of matrix-metalloproteinases-2 and -9 in PMA-differentiated THP-1 macrophages. J Nutr Biochem. 2008 Sep;19(9):594-603. doi: 10.1016/j.jnutbio.2007.08.003. Epub 2007 Dec 21.
• [291] Leukotriene B4 mediates histamine induction of NF-kappaB and IL-8 in human bronchial epithelial cells. Am J Physiol. 1998 Jun;274(6):L1030-9.
• [292] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [293] Signaling in TRPV1-induced platelet activating factor (PAF) in human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G233-40. doi: 10.1152/ajpgi.00409.2009. Epub 2009 Dec 3.
• [294] Comparison of in vitro-activity of commonly used topical glucocorticoids on cytokine- and phospholipase inhibition. Eur J Med Res. 2004 Aug 31;9(8):383-90.
• [295] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [296] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [297] Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
• [298] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [299] A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015 May;43(5):404-413.e5. doi: 10.1016/j.exphem.2015.01.005. Epub 2015 Jan 26.
• [300] Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem. 2006 Aug 11;281(32):22974-82. doi: 10.1074/jbc.M602098200. Epub 2006 May 31.
• [301] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [302] Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.
• [303] Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011 Jul 31;10:95. doi: 10.1186/1476-4598-10-95.
• [304] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [305] The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
• [306] Melatonin enhances hydrogen peroxide-induced apoptosis in human promyelocytic leukaemia HL-60 cells. Mol Cell Biochem. 2011 Jul;353(1-2):167-76. doi: 10.1007/s11010-011-0783-8. Epub 2011 Mar 23.
• [307] Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
• [308] Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther. 2007 Aug;82(2):187-96. doi: 10.1038/sj.clpt.6100214. Epub 2007 May 2.
• [309] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [310] Gene expression responses reflecting 5-FU-induced toxicity: Comparison between patient colon tissue and 3D human colon organoids. Toxicol Lett. 2022 Dec 1;371:17-24. doi: 10.1016/j.toxlet.2022.09.013. Epub 2022 Sep 29.
• [311] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [312] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [313] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.